reports research support grants from Akero, AstraZeneca, Boehringer Ingelheim, BMS, 89bio, Eli Lilly & Company, Intercept, IONIS, Janssen, Madrigal, Metacrine, Merck, NorthSea Therapeutics, Novartis, Novo Nordisk, Oramed, Pfizer, Poxel and Sanofi
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activation has emerged as an important target for protection against OS-related skin diseases such as skin photodamage, and vitiligo
Whether youre currently taking a GLP-1 drug, considering one, or hoping to avoid long-term medication, Jumpstart helps you build the food habits these medications cannot create for you
Retatrutide (LY3437943) is an investigational triple incretin receptor agonist being evaluated in clinical trials for obesity and type 2 diabetes
doi: 10.1186/1475-2875-5-84